The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
03-Oct-24
$1.1 billion
Target:
Tyman plc
Acquiror:
Quanex Building Products Corporation
Advised Tyman plc, a leading international supplier of fenestration components and access solutions to the construction industry, on the recommendation of a cash and share acquisition by Quanex, a global NYSE listed manufacturing company serving OEMs in the fenestration, cabinetry, solar, refrigeration and outdoor products markets
25-Sep-24
Pending
$115 million
Target:
Markforged Holding Corporation
Acquiror:
Nano Dimension Ltd.
Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Markforged, a developer of digital 3D printing solutions in metal and advanced composites
28-Aug-24
Pending
Undisclosed
Target:
EthosEnergy
Acquiror:
One Equity Partners
Advised One Equity Partners, a middle market private equity firm, on the acquisition of EthosEnergy, a global independent turbine and rotating equipment service provider for power and process industries and for aerospace & defense markets
13-Aug-24
Undisclosed
Target:
U.S. Operations of NextStream
Acquiror:
RadiusDC
Advised RadiusDC, a national owner and operator of highly-connected, urban-located data centers, on the acquistion of a series of entities comprising the U.S. operations of NextStream, a data center operator in Latin America owned by Actis
03-Jul-24
Pending
$310 million
Target:
Desktop Metal, Inc.
Acquiror:
Nano Dimension Ltd.
Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Desktop Metal, a vertically integrated 3D printers, materials and software company and pioneer of several 3D printing technologies
09-Apr-24
Undisclosed
Target:
Tegra’s Operating Entities in Honduras, El Salvador, and the U.S.
Acquiror:
SAE-A Trading
Advising Tegra, a premier and leading near and onshore apparel manufacturer for sport, team, and performance apparel, on the sale of its operating entities in Honduras, El Salvador, and the U.S. to SAE-A Trading, a vertically integrated textile and apparel garment manufacturer
14-Feb-24
Undisclosed
Target:
Huntswood CTC Limited
Acquiror:
The Results Companies, LLC
Advised Huntswood CTC Limited, a business process and outsourcing company, on its sale to The Results Companies, LLC (“ResultsCX”), a global Customer Experience Management company backed by ChrysCapital
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
13-Jul-23
$224 million
Target:
Distribuidora Internacional Carmen SAU
Acquiror:
Diploma PLC
Advised Diploma PLC in the acquisition of Distribuidora Internacional Carmen SAU (“DICSA”), a market-leading distributor of fluid power solutions into the European aftermarket
01-Jun-23
$90.4 million
Target:
PCAS Canada Inc.
Acquiror:
DIC Corporation
Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens
27-Apr-23
$403 million
Target:
Distrelec BV
Acquiror:
RS Group plc
Advised RS Group plc on the acquisiton of Distrelec, a high-service, digital-led distributor of industrial MRO and electronic products
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
07-Mar-23
Undisclosed
Target:
David Brown Santasalo
Acquiror:
Stellex Capital Management
Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
28-Jul-22
Pending
$1.6 billion
Target:
Derco Holdings
Acquiror:
Inchcape Plc
Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America
04-Jul-22
$270 million
Target:
Vulcanic
Acquiror:
Spirax-Sarco Engineering plc
Advised Spirax-Sarco Engineering plc, a thermal energy management and niche pumping specialist, on the $270m acquisition of Vulcanic, a French industrial electric heating group and the largest supplier in Europe of bespoke industrial electric heating solutions
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
09-Sep-21
$2.1 billion
Target:
easyJet plc
Acquiror:
N/A
Advising and acting as joint sponsor to UK-based easyJet plc, a leading low-cost European airline carrier, on its £1.2bn fully underwritten rights issue & $400m secured RCF
14-Jul-21
Undisclosed
Target:
New Day Aluminum LLC
Acquiror:
Concord Resources Ltd.
Advised DADA Holdings on the sale of its majority stake in New Day Aluminum LLC to Concord Resources Ltd.
01-Jul-21
$180 million
Target:
British Council’s Indian IELTS operations
Acquiror:
IDP Education Limited
Sole financial adviser to IDP Education, a co-owner and distributor of the IELTS English language test, on the acquisition of the British Council’s Indian IELTS operations
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc